DOP59 Maintenance of remission with tofacitinib in patients with ulcerative colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjz203.098
Abstract: Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Efficacy and safety were demonstrated in 3 Phase 3, randomised, placebo-controlled studies in patients with moderate to severe UC.1 An ongoing,… read more here.
Keywords: octave sustain; remission; study; tofacitinib bid ... See more keywords
AB0440 CHANGES IN KEY LABORATORY VALUES WITH TOFACITINIB 5 MG BID TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.1290
Abstract: Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and rheumatoid arthritis (RA). In most countries where tofacitinib is approved, 5 mg twice daily (BID) is the recommended dose… read more here.
Keywords: tofacitinib bid; pfizer inc; laboratory values; pfizer ... See more keywords
Age-based (
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-218992
Abstract: A randomised, open-label, blinded endpoint post-authorisation safety study (Study A3921133; NCT02092467; database not locked and subject to change) evaluated the safety of tofacitinib 5 mg and 10 mg twice daily (BID) versus tumour necrosis factor inhibitors… read more here.
Keywords: age; age based; based years; tofacitinib bid ... See more keywords